Dia.Pro Diagnostic Bioprobes s.r.l products
COVID-19 - ELISA
ACE2-RBD Neutralization Assay – ELISA
Enzyme ImmunoAssay (ELISA) for the semi-quantitative determination of inhibition activity of RBD-ACE2 binding induced by antibodies to SARS-CoV-2 in human plasma and sera.
COVID-19 Spike 1&2 IgG – ELISA
Enzyme ImmunoAssay (ELISA) for the semi-quantitative determination of IgG antibodies to COVID-19 Spike antigens in human plasma and sera. The IgG assay is intended for testing: (a) health-care workers at risk of COVID-19 infection to verify whether or not they might be positive for potentially neutralizing anti Spike IgG; (b) normal population for epidemiology studies on presence of potential “protective” IgG to COVID-19 Spike antigens; (c) PCR-negative infected individuals, successfully recovered from infection, to assure presence of potentially neutralizing antibodies; (d) human donors, recovered from COVID-19 infection, positive for anti-Spike IgG for the generation of hyperimmune plasma, as a possible immunotherapeutic approach to the disease; (e) vaccinated individuals to assure a reliable positive immunization with development of anti Spike IgG antibodies.
COVID-19 IgG/IgM Confirmation and Typing – ELISA
Module-based Enzyme-Immuno-Assay (ELISA) for the confirmation of samples positive for IgG and IgM antibodies to COVID-19 in first screening. The test is particularly useful in monitoring patients, infected by COVID-19, from the time of symptoms offset up to full recovery. The test can be used in addition to identify (a) the specificity (“typing”) of antibodies to the major immunodominant COVID-19 antigens and (b) identify those samples with a titer of “potentially” neutralizing IgG to Spike antigens such to select the donor as a candidate for immunotherapy, as well.